Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4/6 inhibitors and endocrine therapy
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf123 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Flavia Jacobs und 14 weiteren Autor:innen. Beteiligte Einrichtung: Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 6, Cyclin-Dependent Kinase 4, Protein Kinase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
CDK4/6 inhibitors (CDK4/6i) are cornerstone therapies in Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2−) Breast Cancer (BC) and emerging evidence suggests that they may influence immune function, potentially enhancing antitumor immunity but also triggering autoimmune reactions. This study aims to investigate the prevalence of autoimmune diseases (AD) in patients with HR+/HER2− BC to identify potential predictive biomarkers and to assess the impact of AD on disease progression. Patients and Methods This retrospective-prospective cohort study included consecutive HR+/HER2- BC patients treated with CDK4/6i at Humanitas Research Hospital. Clinical-pathological features, treatment data, AD occurrence, and blood test values were collected. Descriptive statistics were used to determine AD prevalence, Kaplan-Meier method to estimate progression-free survival (PFS), and log-rank test to compare survival curves.
Results
352 patients (median age: 54 years) were enrolled, of which 87.2% had metastatic disease and received palbociclib, abemaciclib, or ribociclib (45.2%, 31.0%, and 23.9%, respectively). 12.8% of patients had early BC and received abemaciclib. ADs were identified in 49 patients: most had pre-existing conditions (38 stable and 4 flaring during treatment) while 7 developed new-onset ADs. The most frequent AD were Hashimoto thyroiditis, vitiligo, and rheumatoid arthritis. In the metastatic setting, the median PFS was significantly longer in patients with AD compared to those without (P = .0013), with patients with flaring or new-onset AD showing a better PFS (P = .0015). No significant predictive biomarkers for AD evolution were found.
Conclusion
CDK4/6i therapy is feasible in patients with pre-existing AD. Interestingly, the onset or flaring of AD during treatment is associated with improved PFS, suggesting a potential immune activation induced by CDK4/6i. However, further robust and prospective studies are required to validate these findings and explore the underlying mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy.
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.
- Department of Medical Oncology, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy.
ORCID-Profile: Alberto Zambelli, Rita De Sanctis
Zitieren
APA
Jacobs, F., Gaudio, M., Andreottola, C., Borroni, R., Benvenuti, C., Saltalamacchia, G., Gerosa, R., Canzian, J., Tiberio, P., Torrisi, R., Masci, G., Miggiano, C., Zambelli, A., Santoro, A., & De Sanctis, R. (2025). Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4/6 inhibitors and endocrine therapy. The Oncologist. https://doi.org/10.1093/oncolo/oyaf123
Vancouver
Jacobs F, Gaudio M, Andreottola C, Borroni R, Benvenuti C, Saltalamacchia G, et al. Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4/6 inhibitors and endocrine therapy. The Oncologist. 2025. doi:10.1093/oncolo/oyaf123
BibTeX
@article{Jacobs2025,
author = {Jacobs, Flavia and Gaudio, Mariangela and Andreottola, Chiara and Borroni, Riccardo and Benvenuti, Chiara and Saltalamacchia, Giuseppe and Gerosa, Riccardo and Canzian, Jacopo and Tiberio, Paola and Torrisi, Rosalba and Masci, Giovanna and Miggiano, Chiara and Zambelli, Alberto and Santoro, Armando and De Sanctis, Rita},
title = {Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4/6 inhibitors and endocrine therapy},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf123}
}
EUVIMED